OTLK (Outlook Therapeutics) Sale Of Business : $0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Outlook Therapeutics Sale Of Business?

Outlook Therapeutics's sale of business for the three months ended in Jun. 2024 was $0.00 Mil. It means Outlook Therapeutics gained $0.00 Mil from selling business. Outlook Therapeutics's sale of business for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Mar. 2024 ), Outlook Therapeutics gained the same money from selling business in Jun. 2024 ($0.00 Mil).

Outlook Therapeutics Sale Of Business Historical Data

The historical data trend for Outlook Therapeutics's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Sale Of Business Chart

Outlook Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sale Of Business

Get a 7-Day Free Trial

Outlook Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Sale Of Business	Get a 7-Day Free Trial															-	-	-	-	-

Outlook Therapeutics Sale Of Business Calculation

The amount earned to sell business.

Sale Of Business for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Outlook Therapeutics Sale Of Business Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLK) » Definitions » Sale Of Business

Comparable Companies

Traded in Other Exchanges

41O:Germany

Address

485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Executives

Lawrence A Kenyon	officer: CFO and Secretary	C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Yezan Munther Haddadin	director	ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844
Jeff Evanson	officer: Chief Commercial Officer	C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Terry Dagnon	officer: Chief Operating Officer	C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Faisal Ghiath Sukhtian	director	7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844
Kurt J Hilzinger	director	1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Julia A Haller	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Trenary C Russell Iii	director, officer: CEO and President	1700 E ST ANDREW PLACE, SANTA ANA CA 92705
Ghiath M. Sukhtian	director, 10 percent owner	7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844
Syntone Ventures Llc	10 percent owner	1517 CHAMPLAIN CREST WAY, CARY NC 27513
Randy H Thurman	director	222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Andong Huang	director	C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852
Gerd Auffarth	director	C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000
Julian S Gangolli	director	4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Gms Ventures & Investments	director	C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007